Company / Current Liabilities
NewAmsterdam Pharma Co N.V. Current Liabilities History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$85.8M
FY2025
5-year range
$36.1M / $106.9M
FY2022-FY2025
Trend
-19.8%
vs FY2024
Sector context
#108 of 214
Health Care
What the data says
At $86M, NewAmsterdam Pharma Co N.V.'s current liabilities ranks #107 of 214 in the Health Care sector. Increased from $50M to $86M over the past 2 years.
Based on SEC 10-K filings.
$86M in FY2025 with a 3-year CAGR of +33.5%.
Increased from $50M to $86M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +33.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#107 of 214 in Health CareTop 50% of 214This company $85.8M Sector average $1.6B
▼
-94.6% below sector average
Key checks
Key Insights
- 3-year CAGR of +33.5%, indicating consistent growth.
- In FY2025, current liabilities decreased 19.8% year-over-year.
- Ranks #108 out of 214 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $85.8M | -19.8% |
| FY2024 | $106.9M | +114.3% |
| FY2023 | $49.9M | +38.4% |
| FY2022 | $36.1M | - |
| FY2021 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026